EventsEventsEventsEvents

  • ABOUT PROMENTIS
    • Management
    • Board of Directors
    • Scientific Advisory Board & Founders
  • TECHNOLOGY
    • SXC-2023
    • TRICHOTILLOMANIA
  • INVESTORS
  • NEWS & RESOURCES
    • Press Releases
    • In the News
    • Publications, Presentations & Events
  • CONTACT
✕

EVENTS

Events

Coming Soon!

PRESS RELEASES

  • Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit
    October 31, 2020
  • Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit
    November 1, 2019
  • Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study
    October 31, 2019
  • Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
    January 17, 2019
Events

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company is developing innovative therapies for neuropsychiatric disorders.



CONTACT US
contact@promentispharma.com
Promentis Pharmaceuticals, Inc.
826 N. Plankinton Ave., Suite 400
Milwaukee, WI 53203

© 2017-2021 Promentis Pharmaceuticals, Inc.
All Rights Reserved.


QUICK LINKS
  • Home
  • About Promentis
  • Technology
  • Investors
  • News & Resources
  • Contact